Borealis Biosciences, Inc.
Borealis Biosciences was founded on the premise that a convergence of scientific and translational breakthroughs is enabling the field of RNA medicines to treat kidney diseases and beyond. The company is backed by founding investor Versant Ventures and Novartis AG, and has a strategic collaboration with the pharma.
Borealis Biosciences, Inc.
Borealis Biosciences develops RNA medicines for kidney diseases, targeting unmet needs to improve patient lives globally.
About
Needs Assessment
Active buying signals and potential business opportunities
Technology Requirements
RNA-based therapeutics delivery systems
Advanced wet lab equipment
Vivarium space
Chemistry and analytical capabilities
Service Requirements
Website design
Contracting with Hane Chow, Inc.
Translational systems biology and data sciences expertise
DMPK and pharmacology services
Translational biology services
Infrastructure Requirements
State-of-the-art wet labs for molecular and cellular biology.
Vivarium space.
Chemistry and analytical capabilities.
Talent Requirements
Expertise in kidney disease
Expertise in targeted delivery of RNA therapeutics
Expertise in translational systems biology
Expertise in data sciences
Expertise in translational biology
Expertise in chemistry
Expertise in DMPK
Expertise in pharmacology
AI Insights
Growth Trajectory
With $180 million in committed capital and strategic partnerships, Borealis Biosciences is poised for significant growth in developing RNA therapies for kidney diseases.
Market Opportunity
Borealis Biosciences has a strong market opportunity in addressing the large unmet need for effective treatments for various kidney diseases using its innovative RNA-based therapeutic approaches.
Access Our Live VC Funding Database
30,000+ funded startups
tracked in the last 3 months
B2B verified emails
of key decision makers
Growth metrics
Real-time company performance data
Live updates
of new VC funding rounds
Advanced filters
for sophisticated queries
API access
with multiple export formats